Allina Health Research is responsible for conducting clinical studies and collaborating with the community’s premier research houses to advance the treatment of our patients. We are committed to the improvement of patient care through discovery.
Allina Health Research collaborates with various health organizations through a variety of clinical trials. With the help of these partnerships, Allina Health is able to create new avenues for treatment.
With over 600 research studies to date, our experienced researchers and collaborators take pride in bettering the medical community and enhancing population health in the communities we serve.
Allina Health Cancer Institute (AHCI) clinical trials are available at Allina Health (Coon Rapids, Minneapolis, St. Paul) and Minnesota Oncology (Coon Rapids, Fridley, Minneapolis) unless otherwise indicated.
AZ Destiny D967RC00001: Phase 3 neoadjuvant study of T-DXd or T-DXd followed by THP compared to ddAC-THP in participants with high-risk HER2+ early-stage breast cancer (PI Perez). *Study pending at Minnesota Oncology locations.
Sea Gen SGNTUC-025 Metastatic HER2+ Breast Cancer Study: Phase 2 study of tucatinib + trastuzumab deruxtecan in previously treated (3rd line) unresectable mHER2+ breast cancer (PI Krie).
Gilead GS-US-586-6144: Phase 2, randomized, open-label study of magrolimab in combination with nab-paclitaxel and paclitaxel versus nab-paclitaxel or paclitaxel in previously untreated unresectable, locally advanced or mTNBC (Phase 2 Cohort 1), magrolimab in combination with sacituzumab govitecan in patients with unresectable, locally advanced or mTNBC who have received 1 prior line of treatment in the unresectable, locally advanced or metastatic setting (Safety Run-in Cohort 2) (PI Krie).
SGNLVA-002 (Part D): Single arm, open-label phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab for first-line treatment of patients with unresectable locally advanced/mTNBC; requires PD-L1 Combined Positive Score (CPS) <10 (PI Krie).
GS-US-548-5916: Phase 2 study of magrolimab combination therapy in patients with 1) untreated unresectable locally advanced/mHNSCC or 2) locally advanced/mHNSCC with 1-2 prior lines of therapy (PI Squillante).
AZ Compel D5162C00042: Phase 3, randomized, double-blind, placebo-controlled study of platinum plus pemetrexed chemotherapy plus osimertinib/placebo in patients with EGFRm, locally advanced/mNSCLC who have progressed extracranially following 1st line osimertinib therapy (PI Squillante).
AZ PAC8 D9075C00001: Phase 3, randomized, double-blind, placebo-controlled, multicenter, international study of durvalumab plus domvanalimab (AB154) in participants with locally advanced (stage 3), unresectable NSCLC who have not progressed following definitive platinum-based concurrent chemoradiation therapy (PI Squillante). *Study pending at Minnesota Oncology locations.
Gilead GS-US-548-5918: Phase 2 study of magrolimab combination therapy in patients with mSCLC with at least 1 prior line of systemic therapy (PI Squillante).
SGNS40-002: Phase 2, open-label study of SEA-CD40 in combination with carbo, pemetrexed and pembrolizumab in subjects with stage IV non-squamous NSCLC (PI Amatruda).
Geistlich GP-2250 1001 Pancreas Cancer Study: Phase 1 trial of GP-2250 + gemcitabine in subjects with advanced unresectable or metastatic pancreatic cancer who have progressed on FOLFIRINOX (PI Squillante). *Not available in St. Paul.
Asieris YHGT-NP-01: Opening Soon - Phase 1/2 open-label multicenter study to evaluate the safety and efficacy of oral APL-1202 in combination with tislelizumab compared to tislelizumab alone as neoadjuvant therapy in patients with muscle invasive bladder cancer (PI Squillante).
Gilead GS-US-548-5918: Phase 2 study of magrolimab combination therapy in patients with mUC who have received 2-3 prior lines of systemic therapy (PI Squillante).
Pacific Edge CXB/2019/US: Biospecimen collection of urine from patients presenting with hematuria for the determination of possible urothelial carcinoma using a multiplexed molecular biomarker test, Cxbladder ("STRATA Study") (PI Konety).
Exact Sciences ASCEND2: Biospecimen collection to detect cancers earlier through elective plasma-based CancerSEEK testing in patients >50 years (PI Squillante).
OR
LAM 001-2018 ELITE Protocol: Biospecimen collection of blood from patients with cancer and/or benign disease (PI Squillante).
If interested in more information regarding the previous studies, please call the Allina Health Cancer Institute Research Bridge Line: 612-863-8716
No current clinical trials.
If you are interested in learning more about any Neuroscience Research trials, please contact the Neuroscience Research Team at NeuroscienceResearch@allina.com
Neuro-Oncology Research Trials:
GBM AGILE: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent Glioblastoma (GBM).
Summary:
Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed (ND) and recurrent GBM.
More Information: https://clinicaltrials.gov/ct2/show/NCT03970447
DB102-01: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Enzastaurin Added to Temozolomide During and Following Radiation Therapy in Newly Diagnosed Glioblastoma Patients Who Possess the Novel Genomic Biomarker DGM1.
Summary:
This randomized, multi-center phase III study will evaluate enzastaurin in comparison to a placebo, when added to radiation therapy and TMZ treatment. Eligible Glioblastoma (GBM) participants will be randomly assigned to one of the following groups:
More Information: https://clinicaltrials.gov/ct2/show/NCT03776071
STaRT Registry: A Multicenter Observational Study of GammaTile™ Surgically Targeted Radiation Therapy (STaRT) in Intracranial Brain Neoplasms.
Summary:
This is a registry study aimed at evaluating real-world clinical outcomes and patient reported outcomes that measure the effectiveness and safety of GammaTiles.
More Information: https://clinicaltrials.gov/ct2/show/NCT04427384
EF-32 (TRIDENT): A Pivotal, Randomized, Open-Label Study of OPTUNE® (TTFIELDS, 200KHZ) Concomitant With Radiation Therapy and Temozolomide for the Treatment of Newly Diagnosed Glioblastoma.
Summary:
This study is designed to test the effectiveness and safety of Optune® given concomitantly with radiation therapy (RT) and temozolomide (TMZ) in newly diagnosed GBM patients, compared to radiation therapy and temozolomide alone. In both arms, Optune® and maintenance temozolomide are continued following radiation therapy.
More Information: https://clinicaltrials.gov/ct2/show/NCT04471844
Neuro-interventional Radiology Research Trials:
WEB-PAS: Post-Market Surveillance Study to Evaluate the Long Term Safety and Effectiveness of the WEB® Device.
Summary:
This is a Post-Market Surveillance study of the FDA-approved WEB Device. The WEB is an intra-aneurysmal device intended for use in endovascular embolization of intracranial aneurysms. The intended therapeutic effect of the WEB device is to line the neck of the aneurysm with a metallic structure that disrupts the inflow of blood, causing hemostasis within the aneurysm sac, and leading to thrombus formation within the implant.
More Information: https://clinicaltrials.gov/ct2/show/NCT04839705
THUNDER: Acute Ischemic Stroke Study with the Penumbra System® including Thunderbolt™ Aspiration Tubing.
Summary:
The objective of this study is to demonstrate the safety and efficacy of the Penumbra System including Thunderbolt Aspiration Tubing (Thunderbolt) in a population presenting with acute ischemic stroke (AIS) secondary to intracranial large vessel occlusion (LVO) who are eligible for mechanical thrombectomy.
More Information: https://clinicaltrials.gov/ct2/show/NCT05437055
PRECISE: Perfusion imaging to identify posterior circulation candidates for thrombectomy
Summary:
Strokes are often caused by a blood clot inside a blood vessel that blocks the normal blood flow to a part of the brain; this type of stroke is called an ischemic stroke. The blockage can result in permanent brain damage. We are looking to enroll participants with an ischemic stroke due to a blockage of one of the vessels that supplies blood to the back of the brain. The purpose is to find out if advanced brain imaging can help identify which participants are most likely to benefit from a procedure to remove the blood clot to restore the blood flow to the brain.
Stroke Research Trials:
ARCADIA: AtRial Cardiopathy and Antithrobotic Drugs In prevention After cryptogenic stroke.
Summary:
ARCADIA is a phase 3 clinical trial of apixaban versus aspirin in patients who have evidence of atrial cardiopathy and a recent stroke of unknown cause. Eleven hundred subjects will be recruited over 2.5 years at up to 200 sites in and out of the NINDS StrokeNet consortium. Subjects will be followed for a minimum of 1.5 years and a maximum of 7 years on this trial.
More information: https://clinicaltrials.gov/ct2/show/NCT03192215
ASPIRE: Anticoagulation in Intracerebral Hemorrhage (ICH) Survivors for Stroke Prevention and Recovery. [PI: Dr. Mark Young, Lead Coordinator: Kaitlin Lundell]
Summary:
ASPIRE is a randomized, double-blinded, phase III clinical trial designed to test the efficacy and safety of apixaban (Eliquis®), compared with aspirin, in patients with a recent ICH and high-risk non-valvular AF . Patients will be enrolled over 3.5 years and followed for study outcomes for a minimum of 12 months and maximum of 36 months.
More information: https://clinicaltrials.gov/ct2/show/NCT03907046
Thank you for your interest in our studies. All recruitment for studies is currently suspended due to COVID-19. Please check back for updates.
No current clinical trials.